Related Experiment Video
Updated: May 30, 2026

03:55
Computer-Aided Three-Dimensional Visualization in the Treatment of Locally Advanced Thyroid Cancer
Published on: June 9, 2023
Update on external beam radiation therapy in thyroid cancer
1Department of Radiation Oncology, Princess Margaret Hospital, Toronto, Ontario, Canada. James.brierley@rmp.uhn.on.ca
The Journal of Clinical Endocrinology and Metabolism
|August 6, 2011
Summary
External beam radiotherapy (EBRT) shows promise when combined with taxanes for anaplastic thyroid cancer. Recent evidence also supports EBRT for high-risk differentiated thyroid cancer, with advances improving accuracy and reducing toxicity.
Area of Science:
- Oncology
- Radiotherapy
Background:
- Surgery is the primary treatment for thyroid cancer.
- The role of external beam radiotherapy (EBRT) is established in anaplastic thyroid cancer but debated in differentiated and medullary thyroid cancer.
Purpose of the Study:
- To review recent advancements and evidence regarding the use of EBRT in various types of thyroid cancer.
- To discuss the efficacy of combining EBRT with taxanes and the impact of new delivery techniques.
Main Methods:
- Review of recent literature on EBRT in anaplastic, differentiated, and medullary thyroid cancer.
- Analysis of studies combining EBRT with taxanes.
- Discussion of advancements in intensity-modulated radiation therapy (IMRT) and image-guided radiation therapy (IGRT).
Main Results:
- Successful outcomes reported for combining EBRT with taxanes in anaplastic thyroid cancer.
- Evidence from large institutions supports EBRT for high-risk differentiated thyroid cancer.
- Advances in IMRT and IGRT enhance radiation delivery accuracy and reduce toxicity.
Conclusions:
- EBRT, particularly when combined with taxanes, shows potential in anaplastic thyroid cancer treatment.
- Current evidence supports the use of EBRT in specific high-risk differentiated thyroid cancer cases.
- Technological advancements in EBRT delivery are improving treatment efficacy and patient safety across thyroid cancer types.

